Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stone, N. N.
Right arrow Articles by Clejan, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stone, N. N.
Right arrow Articles by Clejan, S. J.

Journal of Andrology, Vol 12, Issue 6 376-380, Copyright © 1991 by The American Society of Andrology

JOURNAL ARTICLE

Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia

N. N. Stone and S. J. Clejan
Department of Urology, Mt. Sinai School of Medicine, New York, New York.

Patients diagnosed as having benign prostatic hyperplasia (BPH) had determination of prostate volume (PV), prostate-specific antigen (PSA), and serum testosterone before consideration for entry into a double-blind, randomized trial of flutamide (750 mg/day for 6 months). The mean PSA level for these patients (N = 43) was 7.6 ng/ml (range: 1.0 to 45.7), and the mean PV was 76.8 cm3 (range: 24 to 198). Linear regression analysis demonstrated a strong correlation between the two (r = 0.876, P less than 0.05). Every 10 cm3 of prostate volume accounted for 1.02 ng/ml of PSA in the serum. Twenty-two patients (11 treated with flutamide, 11 with a placebo) agreed to enter the study. Prostate volume decreased by 35% and PSA by 65% (P less than 0.001) within 6 months. These changes occurred despite a 58.3% increase in serum testosterone levels (P less than 0.01). Patients treated with a placebo experienced no significant changes. Side effects were minimal, and flutamide was well tolerated. These data suggest that androgen deprivation therapy with flutamide may be an effective and safe treatment for BPH.


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. J. McPherson, S. Hussain, P. Balanathan, S. L. Hedwards, B. Niranjan, M. Grant, U. P. Chandrasiri, R. Toivanen, Y. Wang, R. A. Taylor, et al.
Estrogen receptor-{beta} activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNF{alpha} mediated
PNAS, February 16, 2010; 107(7): 3123 - 3128.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. J. Padayatty, M. Marcelli, T. C. Shao, and G. R. Cunningham
Lovastatin-Induced Apoptosis in Prostate Stromal Cells
J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1434 - 1439.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by The American Society of Andrology.